Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,618 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy for Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria.
Nemoto Y, Ishihara H, Nakamura K, Tachibana H, Fukuda H, Yoshida K, Kobayashi H, Iizuka J, Shimmura H, Hashimoto Y, Tanabe K, Kondo T, Takagi T. Nemoto Y, et al. Among authors: fukuda h. Target Oncol. 2022 Jul;17(4):475-482. doi: 10.1007/s11523-022-00896-9. Epub 2022 Jul 5. Target Oncol. 2022. PMID: 35789472
Impact of Body Mass Index on Outcomes in an Asian population of Advanced Renal Cell Carcinoma and Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors.
Ishihara H, Ishiyama Y, Nemoto Y, Nakamura K, Tachibana H, Fukuda H, Yoshida K, Kobayashi H, Iizuka J, Shimmura H, Hashimoto Y, Tanabe K, Kondo T, Takagi T. Ishihara H, et al. Among authors: fukuda h. Clin Genitourin Cancer. 2023 Feb;21(1):136-145. doi: 10.1016/j.clgc.2022.08.001. Epub 2022 Aug 6. Clin Genitourin Cancer. 2023. PMID: 36031535
Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study.
Ishihara H, Nemoto Y, Nakamura K, Tachibana H, Ikeda T, Fukuda H, Yoshida K, Kobayashi H, Iizuka J, Shimmura H, Hashimoto Y, Kondo T, Takagi T. Ishihara H, et al. Among authors: fukuda h. Target Oncol. 2023 Mar;18(2):209-220. doi: 10.1007/s11523-023-00956-8. Epub 2023 Mar 21. Target Oncol. 2023. PMID: 36941516
Association Between Kidney Function and Outcomes Following Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Carcinoma.
Ishihara H, Nemoto Y, Tachibana H, Ikeda T, Fukuda H, Yoshida K, Kobayashi H, Iizuka J, Shimmura H, Hashimoto Y, Kondo T, Takagi T. Ishihara H, et al. Among authors: fukuda h. Clin Genitourin Cancer. 2024 Apr;22(2):549-557.e5. doi: 10.1016/j.clgc.2024.01.010. Epub 2024 Jan 15. Clin Genitourin Cancer. 2024. PMID: 38281878
3,618 results